FDA's GLP-1 import alert: what the September 2026 update adds and why one Green List manufacturer is now under scrutiny

What Import Alert 66-80 is and how it works

Import Alert 66-80, formally titled "Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances," is an administrative mechanism that allows FDA field officers at U.S. ports of entry to detain incoming shipments of GLP-1 active pharmaceutical ingredients without inspecting them first.[1] The legal basis is a finding that the products appear adulterated under Section 501 of the Federal Food, Drug, and Cosmetic Act.[1]

Before the alert existed, FDA could detain a shipment only after physical sampling. Under the alert, detention becomes the default for non-listed manufacturers. The burden shifts to the importer: to get a shipment released, the company must submit evidence — certificates of analysis, manufacturing records, stability data, chain-of-custody documentation — demonstrating the ingredient meets CGMP standards.[1]

The Green List is the exception. Manufacturers that have passed an FDA inspection or submitted sufficient records are exempted from automatic detention. Their shipments can still be sampled, but they are not subject to the alert's default hold.[1][2]

Why the agency built it in the first place

The alert originated in September 2025, when GLP-1 drug shortages had pushed a large share of the market toward compounding pharmacies, many of which sourced bulk API from overseas suppliers. The FDA evaluated 48 foreign GLP-1 API manufacturing sites and found 10 — roughly 21 percent — noncompliant with basic manufacturing standards under Section 501.[1][2]

The agency also described a specific evasion pattern: manufacturers registering with FDA, offering API for U.S. import, refusing records requests, and then deregistering — all within a short window.[1] The pattern suggested some suppliers were cycling in and out of the FDA's tracking system to avoid scrutiny. Registration theater, with a real-looking FDA establishment number on the sales deck and no intention of sustaining compliance.

Since those shortages, courts have held that the semaglutide and tirzepatide shortage designations have ended. The Fifth Circuit upheld FDA's position in August 2026, citing Novo Nordisk's capacity of roughly 5.8 million packages per month against about 520,000 compounded packages.[3] That ruling legally narrowed the pathway for compounding pharmacies to continue producing these drugs. But Import Alert 66-80 remained on the books, and its September 2026 revision expanded it further.

What the September 2026 revision added

The September 21, 2026 update made two material changes. First, it added new FDA product codes to the alert's scope: four codes under the "Hormone N.E.C." category (product code 64R) covering non-sterile powder, sterile powder, and API forms intended for further manufacturing or prescription compounding.[1] Adding these broader codes gives FDA import field staff authority to detain a wider range of peptide-adjacent shipments under the same mechanism, not just compounds that fit an existing named GLP-1 drug code.

Second, orforglipron API appeared on the Green List for the first time.[1] Orforglipron, sold under the brand name Foundayo, is Lilly's oral non-peptide GLP-1 receptor agonist approved by the FDA on April 1, 2026. Unlike semaglutide and tirzepatide, orforglipron is a small molecule, not a peptide. The FDA listed three manufacturers for the API and one for an orforglipron solid-dispersion drug product intermediate, with sites identified by country: two in China, one in Ireland, and the intermediate in Portugal.[1]

Unlike the semaglutide and tirzepatide entries, which use separate product subcodes distinguishing API intended "for further manufacturing" from API "for Rx compounding," orforglipron appears under a single product code without that distinction.[1][4] At least one legal analysis has noted that this framing does not create a compounding authorization — Green List status exempts a manufacturer from automatic detention, it does not authorize the underlying compounding — but the single code is ambiguous about intended end use.[4]

The Harbin case: a Green List fraud allegation

Among the more serious disclosures in the August 2026 revision of the alert was a description of Harbin Jixianglong Biotech, a Chinese API manufacturer that had been placed on the Green List.[2][4] FDA described conduct that, if accurate, would be a direct circumvention of the alert's purpose: Harbin allegedly obtained semaglutide API from a facility that was not on the Green List, relabeled it under Harbin's name, altered manufacturing and retest records, and shipped the product into U.S. commerce.[2] The agency said this conduct may have been an attempt to evade Import Alert 66-80.[2]

Harbin's status on the Green List at the time meant its shipments were presumptively trusted. The allegations, if borne out, would mean a trusted manufacturer used that status as a conduit for product from an untrusted one. FDA has not published a charging document or criminal referral in connection with the Harbin situation, and the company's regulatory status should be understood as an allegation by FDA, not a proven finding.[2]

The case has drawn a response from at least one external analyst who published an appeal in September 2026 arguing the Green List mechanism should be shut down entirely on the grounds that firm-level trust credentials are reusable by bad actors, the list is redacted so the public cannot audit it, and FDA's own noncompliance data shows the supply chain warrants universal scrutiny rather than presumptive trust.[4]

What this means for the research peptide supply chain

Import Alert 66-80 covers bulk API entering the United States, not finished research vials already in circulation. The alert applies at the border, and its effect on any particular research supplier depends on where that supplier's upstream API originates and whether that upstream manufacturer is on the Green List or has passed an independent customs review.[1]

The expansion of the alert to cover "Hormone N.E.C." product codes is the most directly relevant change for the broader peptide market. Those codes were not in the original alert and bring a wider range of peptide-adjacent bulk substance shipments under default detention authority.[1] What that means in practice depends on how FDA field officers apply the codes at specific ports, which is not spelled out publicly in the alert itself.

The fraud allegation against Harbin has a separate implication for anyone relying on COAs or supplier claims without independent testing: the company whose name is on the paperwork is not always the company that made the product.[2][4] FDA's own summary of the situation is a fairly direct statement that import documentation in this supply chain has been falsified by at least one Green List manufacturer.

Frequently asked questions

Sources and further reading

1. Import Alert 66-80 — FDA (revised September 21, 2026)
2. FDA GLP-1 'Green List' Faces Shutdown Call Over Counterfeit API Risk — PepsReview
3. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — FDA
4. Through the Green List — RxBorderDefense.com

Related reading

• FDA moves to permanently close bulk compounding of GLP-1 drugs: what the proposed rule means
• What the FDA's July 2026 peptide compounding vote actually changes
• Empower Pharmacy FDA warning: what the September letter establishes